Abstract 2208
Background
There is limited information on the association among complementary medicin (CM), toxicities and overall survival of patients with cancer who receive CM compared with those who do not.
Methods
This is a prospective study including 223 patients collected during 6 months between July 15, 2018 and January 15, 2019 in the department of medical oncology at the Habib Bourguiba university Hospital. All patients were questioned about the concept of taking herbs and botanicals such as gravila and Alinda. We analyzed the demographic data, the toxicities after the consumption of plants as well as the causal link. Then we compared overall survival among those who receive plants versus the non-users.
Results
The average age was 53 years (2-86 years old). There were 152 women and 71 men. 83 patients were illiterate (37.2%). 110 patients had breast cancer (49.3%), the others included colorectal, endometrial, cervical, gastric, ovarian, lung, bladder and head and neck cancers). 97 had metastatic disease (43.4%). 97 patients had taken plants (43.4%), during the medical treatment in 57 cases (58.7%). 60 patients had consumed Alinda (61.8%) and 36 patients had received Graviola (37.1%). 62 women had taken plants against 37 men (χ2 = 1.425, ddl = 1, α = 5%, p = 0.147). 49 patients with metastatic disease had taken plants against 48 with localized cancer (χ2 = 3.468, ddl = 2, α = 5%, p = 0.177). 10 patients have had diarrhea (10.3%), 10 cytolysis (10.3%), 11 cholestasis (11.3%), 15 thrombocytosis (15.4%), 17 leukocytosis (17.5%) and 13 anemia (13.4%). Only leukocytosis, thrombocytosis, and diarrhea were related to plant consumption with p = 0.0001, p = 0.016 and p = 0.014 respectively. Overall survival at 5 years was 67.1%. It was lower in patients consuming the plants (54% vs 83% p = 0.023).
Conclusions
The consumption of Graviola and Alinda was associated with a decrease in the 5 years overall survival (p = 0.023). It was associated with leukocytosis, thrombocytosis, and diarrhoea. This consumption was not statistically different between men and women nor between the localized or metastatic stage.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5037 - CXCR4, CCR2 and CCR5 expression in subsets of tumor cells with stem and/or EMT features
Presenter: Olga Savelieva
Session: Poster Display session 1
Resources:
Abstract
5729 - Expression of mutant p53 affects cancer cell sensitivity to topotecan
Presenter: Rimma Mingaleeva
Session: Poster Display session 1
Resources:
Abstract
5725 - Breast cancer organoids a new tool for the prediction of drugs penetration and patient’outcome
Presenter: Giuseppina Roscigno
Session: Poster Display session 1
Resources:
Abstract
5680 - Aptamer-mediated exosomes detection for early breast cancer identification.
Presenter: Cristina Quintavalle
Session: Poster Display session 1
Resources:
Abstract
2460 - MicroRNA-181c promotes tamoxifen resistance in breast cancer cells via upregulation Akt/mTOR axis
Presenter: Alexander Scherbakov
Session: Poster Display session 1
Resources:
Abstract
3751 - Spatio-temporal separation of tumor infiltrating CD8+ T-cells and HER2/neu+ tumor cells in tumor-immune milieu of infiltrating ductal carcinoma of the breast
Presenter: Sandhya Sreedharan
Session: Poster Display session 1
Resources:
Abstract
4664 - Large genomic rearrangements in BRCA1 and BRCA2 genes in the Portuguese population.
Presenter: Joao Pinto
Session: Poster Display session 1
Resources:
Abstract
4611 - Non-BRCA1/2 hereditary breast and ovarian cancer: findings from a multidisciplinary program
Presenter: Ana Monteiro
Session: Poster Display session 1
Resources:
Abstract
5340 - Quantitative imaging and characterization of collagen patterns in high grade serous ovarian carcinoma (HGSOC)
Presenter: Ruby Huang
Session: Poster Display session 1
Resources:
Abstract
4209 - Semiquantitative assessment of vimentin expression in prostate cancer (PC)
Presenter: Marina Puchinskaya
Session: Poster Display session 1
Resources:
Abstract